Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open label extension study for long-term safety of fenfluramine in Myoclonic Astatic Epilepsy
DRKS00023837Phase 2Active, not recruiting
- Sponsor
- Universitätsklinikum Schleswig-Holstein
- Start
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fenfluramine in Genetic generalized epilepsy (GGE), generalized epilepsy and myoclonic astatic epilepsy (MAE), sponsored by Universitätsklinikum Schleswig-Holstein. Primary endpoint: Long-term safety of fenfluramine. Started May 2022; status: active, not recruiting.
02
Drugs
fenfluramine
03
Conditions
Genetic generalized epilepsy (GGE)generalized epilepsymyoclonic astatic epilepsy (MAE)
Beyond the preview
Go deeper on DRKS00023837.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00023837.